Researchers from the Chinese Academy of Medical Sciences reported the discovery of the 1,2,4-oxadiazole derivative FO-4-15 for the treatment of Alzheimer’s disease (AD).

The draft Medicare physician fee schedule for calendar year 2025 provoked a strong backlash from physician societies due to a ...

Researchers from Johnson & Johnson presented the discovery of a novel inhibitor of cyclin-dependent kinase 7 (CDK7), a ...

In what represents its first patenting, Roseville, Minn.-based Iveacare Inc. provides insights as to what its first ...

DNA is open and accessible, while the action of an epigenetic editor turns it into functionally inactive DNA, which is closed ...

The specter of elevated liver enzymes, a known problem with the drug class, became a topic of talk with regard to Sanofi SA’s ...

Following the recent recommendation of its advisory committee, the U.S. FDA gave the nod to Zevra Therapeutics Inc.’s ...

Rakuten Medical Inc. has presented preclinical results with RM-0256, a PD-L1-targeted photoimmunotherapy, showing its ability ...

As med-tech startups look to raise capital without diluting the valuation of their company, many may look to sell ...

Creo Medical Group plc entered into an agreement to sell a 51% stake in its European consumable business to Chinese medical ...

Australia is the skin cancer capital of the world, but with a shortage of dermatologists, patients often wait too long to get ...

Boehringer Ingelheim Pharma GmbH & Co. KG has synthesized NADPH oxidase 4 (NOX4) inhibitors reported to be useful for the treatment of atherosclerosis, cancer, pulmonary hypertension, inflammatory ...